Evidence map›Paper›PMID 40502633›Full record

ReviewFrontiers in oncology2025

The epidemiology, etiology, and future prophylactic options for cancers in Mainland China.

Hongsen Chen, Jie Xu, Wenbin Liu, Xi Chen, Ping Li, Guangwen Cao

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongsen Chen *Shanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai, China.
Jie Xu *Center of International Scholar Exchange, Second Military Medical University, Shanghai, China.
Wenbin LiuShanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai, China.
Xi ChenShanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai, China.
Ping LiShanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai, China.
Guangwen CaoShanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mainland China accounts for 18.66% of the world's population, 24.17% of global cancer new cases, and 26.44% cancer-related death worldwide in 2022. We aim to characterize the spatiotemporal distribution patterns of cancer burden, elucidate the main causes of high cancer burden, and propose evidence-based strategies for the prevention and control of major cancer types in Mainland China. We conducted a systematic search for relevant articles in PubMed and CNKI. We also analyzed the related data from two key databases: the 2022 dataset of the International Agency for Research on Cancer (IARC) and the records of China's National Mortality Surveillance System (from 2004 - 2018). Lung cancer, primary liver cancer (PLC), gastric cancer, colorectal cancer (CRC), and esophageal cancer accounted for 67.50% of all cancer-related deaths. Age-standardized incidence rates (ASIR) and mortality rates (ASMR) of PLC, gastric cancer, and esophageal cancer showed downward trends, while their crude rates kept increasing. The ASMR of lung cancer kept decreasing in urban but increasing in rural populations. The burden of CRC kept increasing. Increase in cancer incidence could be attributed to the co-existence of the poverty-related risk factors like chronic infections and affluence-related ones like metabolic disorders. Primary prevention targeting to these modifiable risk factors is cost-effective. Aerobic exercise could decrease cancer occurrence and cancer-related death via decreasing systemic low-grade inflammation. The second and tertiary prophylactic options should be epidemiologically optimized. Targeting the major risk factors co-existed during economic transformation should be a cost-effective strategy to decrease cancer burden in transforming countries.

Indexed as

cancer epidemiologyChina’s cancer burdenchronic inflammationmodifiable risk factorsprevention strategiessystemic interventions

Identifiers

PMID40502633
PMCPMC12151843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.